huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Enrolling By Invitation
18-99 years
All
Phase
1
30 participants needed
1 Location
Brief description of study
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Pancreatic Cancer,Ovarian Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older, Histologically confirmed unrespectable or metastatic pancreatic adenocarcinoma; OR Persistent or recurrent serous epithelial ovarian cancer
Updated on
01 Aug 2024.
Study ID: 849937
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
